Akero Therapeutics Inc
Akero Therapeutics, Inc. engages in developing transformational treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of metabolic… Read more
Akero Therapeutics Inc (AKRO) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.070x
Based on the latest financial reports, Akero Therapeutics Inc (AKRO) has a cash flow conversion efficiency ratio of -0.070x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-67.17 Million) by net assets ($957.64 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Akero Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Akero Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Akero Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Akero Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shanghai Putailai New Energy Technology Co.Ltd.
SHG:603659
|
0.021x |
|
Toto Ltd
PINK:TOTDY
|
0.035x |
|
SLM Corp
NASDAQ:SLM
|
0.372x |
|
Jiangsu Etern Co Ltd
SHG:600105
|
0.016x |
|
ServiceTitan, Inc. Class A Common Stock
NASDAQ:TTAN
|
0.029x |
|
Nexans S.A
PINK:NXPRF
|
0.250x |
|
Compal Electronics Inc
TW:2324
|
0.069x |
|
PT. Chandra Asri Petrochemical Tbk
PINK:PTPIF
|
0.029x |
Annual Cash Flow Conversion Efficiency for Akero Therapeutics Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of Akero Therapeutics Inc from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $750.11 Million | $-230.11 Million | -0.307x | -12.96% |
| 2023-12-31 | $535.31 Million | $-145.37 Million | -0.272x | +4.15% |
| 2022-12-31 | $326.56 Million | $-92.52 Million | -0.283x | +39.87% |
| 2021-12-31 | $169.11 Million | $-79.68 Million | -0.471x | -72.17% |
| 2020-12-31 | $258.71 Million | $-70.80 Million | -0.274x | +1.12% |
| 2019-12-31 | $128.73 Million | $-35.63 Million | -0.277x | -398.72% |
| 2018-12-31 | $-49.92 Million | $-4.62 Million | 0.093x | -90.35% |
| 2017-12-31 | $-4.56 Million | $-4.38 Million | 0.960x | -- |